3 documents found, page 1 of 1
Improving non-small-cell lung cancer survival through molecular characterizatio...
Fernandes, M. G. O.; Vilariça, A. S.; Fernandes, B.; Camacho, C.; Saraiva, C.; Estevinho, F.; Bastos, H. Novais e; Lopes, J. M.; Fidalgo, P.The management of NSCLC remains challenging, and the integration of data from predictive biomarkers in routine clinical practice can contribute to an optimal, individualized patient approach, particularly given the rapid emergence of effective targeted therapies. When considering molecular biomarker testing, the choice of the biomarker panel, target population, testing approach, and turnaround time are key issu...
108P PICTuRE: Real-world treatment pathways in stage III non-small cell lung ca...
Teixeira, M.E.; Oliveira Fernandes, M.G.; Ferreira, M.L.S.; Estevinho, F.; Lopes, J.A.; Araújo, A.; Pacheco Figueiredo, M.M.; Barradas Lopes, M.L.Stage III NSCLC is a heterogeneous and complex setting that requires multimodal management. Recent advances in modern medicine led to the implementation of immuno-oncology (IO) into clinical practice. PICTuRE aims to assess the clinical management and the IO impact on clinical outcomes in stage III NSCLC patients (pts).
Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in ...
Figueiredo, A.; Almeida, M.A.; Almodovar, M.T.; Alves, P.; A, Araujo; Araújo, D.; Barata, F.; Barradas, L.; Barroso, A.; Brito, U.; Camacho, E.Objective: The main aim of the study was to evaluate the efficacy and safety profile of Nivolumab, an immune-checkpoint-inhibitor antibody, in advanced, previously treated, Non-Small Cell Lung Cancer (NSCLC) patients, in a real world setting. Methods: We performed a retrospective, multicentre data analysis of patients who were included in the Portuguese Nivolumab Expanded Access Program (EAP). Eligibility crite...